Ascendis Pharma A/S - ADR

Name: Ascendis Pharma A/S - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Ascendis Pharma A/S - ADR

Stock Card

$249.37

$-0.88 (-0.35%)

As on 27-Aug-2026 13:37EDT

Market cap

$16,614 Mln

Revenue (TTM)

$1,054 Mln

P/E Ratio

19.4

P/B Ratio

10.1

Div. Yield

0 %

Ascendis Pharma A/S - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 248.41 High: 250.52

52 Week Range

Low: 186.05 High: 282.15

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

1.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

73.2
Debt to Equity

0
Book Value

$--
EPS

$11.5
Face value

--
Shares outstanding

65,592,830

10 Years Aggregate

CFO

€-2,184.14 Mln

EBITDA

€-2,320.00 Mln

Net Profit

€-2,450.27 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Ascendis Pharma A/S - ADR	16.9	-1.8	4.1	26.8	36.1	10.7	30.3
BSE Sensex	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Ascendis Pharma A/S - ADR	54.9	9.2	3.1	-9.2	-19.3	19.9	122.1
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Ascendis Pharma A/S - ADR

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients... with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Read more

President, CEO, Member of Executive Board & Executive Director

Mr. Jan Moller Mikkelsen
President, CEO, Member of Executive Board & Executive Director

Mr. Jan Moller Mikkelsen
Headquarters

Hellerup
Website

https://ascendispharma.com

FAQs for Ascendis Pharma A/S - ADR

What is the current share price of Ascendis Pharma A/S - ADR Today?

The share price of Ascendis Pharma A/S - ADR is $249.37 (NASDAQ) as of 27-Aug-2026 13:37 EDT. Ascendis Pharma A/S - ADR has given a return of 36.1% in the last 3 years.

What is the current PB & PE ratio of Ascendis Pharma A/S - ADR?

The P/E ratio of Ascendis Pharma A/S - ADR is 19.38 times as on 21-Aug-2026.
The P/B ratio of Ascendis Pharma A/S - ADR is 10.05 times as on 21-Aug-2026, a 88 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-59.76	-80.42
2024	-21.77	-77.86
2023	-14.81	-48.94
2022	-11.73	25.97
2021	-18.89	8.20

What is the 52 Week High and Low of Ascendis Pharma A/S - ADR?

The 52-week high and low of Ascendis Pharma A/S - ADR are Rs 282.15 and Rs 186.05 as of 27-Aug-2026.

What is the market cap of Ascendis Pharma A/S - ADR?

Ascendis Pharma A/S - ADR has a market capitalisation of $ 16,614 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Ascendis Pharma A/S - ADR?

Before investing in Ascendis Pharma A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.